Author Interviews, Breast Cancer, NEJM / 05.06.2014
Premenopausal Breast Cancer: Ovarian Suppression with Exemestane
MedicalResearch.com Interview with:
Dr. Olivia Pagani
Institute of Oncology of Southern Switzerland
Ospedale San Giovanni, Switzerland
MedicalResearch: What are the main findings of the study?
Dr. Pagani: The studies show that also in premenopausal women (as already proven in postmenopausal women), aromatase inhibitors (AIs) (in this case Exemestane) given as adjuvant treatment are more effective than Tamoxifen in women with hormone receptor positive early breast cancer who are given concomitantly ovarian suppression to lower estrogen production. The 28% improvement in disease free survival is comparable to that seen in postmenopausal women. In particular, outcomes in women who did not receive chemotherapy (43% of the entire population, 29% of whom with node positive disease) were strikingly good (<97% were breast cancer free at 5 years).
(more…)